Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623766 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT00623766: Completed Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
NCT00623766 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 99 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623766, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
Primary Outcome
Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) (global, in brain, or outside of brain) based on mWHO criteria divided by the number of patients who received treatment. By mWHO criteria: CR=complete disappearance of all index lesions. PR=decrease, relative to baseline, of 50% or greater in the sum of the 2 largest perpendicular diameters of all index lesions. SD=does not meet criteria
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Corticosteroid: Betamethasone
- DRUG Corticosteroid: Dexamethasone
- DRUG Corticosteroid: Fludrocortisone
- DRUG Corticosteroid: Hydrocortisone
Study Locations (14)
California
- City Of Hope - Duarte
- The Angeles Clinic & Research Institute - Los Angeles
Illinois
- Loyola University Medical Center - Maywood
- Oncology Specialists, S.C. - Park Ridge
New York
- Memorial Sloan Kettering Cancer Center - New York
- Local Institution - The Bronx
Arizona
- Mayo Clinic Arizona - Scottsdale
Connecticut
- Yale University School Of Medicine - New Haven
Indiana
- Indiana University Cancer Center - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT00623766 record still lists
NCT00623766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Ipilimumab is the first listed.
NCT00623766 lists 14 locations in 11 states (California, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT00623766 about?
NCT00623766 is a clinical study titled "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases". To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
What is the current status of trial NCT00623766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2008-07. Estimated completion is 2012-10.
What conditions does trial NCT00623766 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00623766?
The interventions under investigation include: Ipilimumab (DRUG), Corticosteroid: Betamethasone (DRUG), Corticosteroid: Dexamethasone (DRUG), Corticosteroid: Fludrocortisone (DRUG), Corticosteroid: Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT00623766?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623766 being conducted?
This trial has 14 study locations across Arizona, California, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00623766's enrollment target sits among peer trials
99 113th of 266 higher than 154 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia